EDGEWELL PERSONAL CARE Co — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Edgewell reported Q3 FY2026 net sales of $570.1M (+1.7% YoY), with organic growth of +1.1%, driven by North America (+3.0% organic). Adjusted EPS held flat at $0.72 vs. prior year; adjusted EBITDA declined to $78.9M from $81.2M. Full-year guidance narrowed: adjusted EPS now $1.80–$2.00 (midpoint $1.90, unchanged), adjusted EBITDA $250–$260M (midpoint $255M, unchanged), but reported EPS guidance lowered to flat–$0.20 from flat–$0.40. Restructuring charges of $24.5M in Q3 ($92M full-year guidance increased from $90M). Cash position strong at $397.1M; dividend held at $0.15/share.
Why this rating
Organic growth resumption and beat on adjusted metrics are modest positives; flat adjusted EPS YoY and EBITDA decline offset gains. Narrow guidance (range reduced ~$0.20 EPS) and elevated restructuring costs signal execution risk. Event is ~3% of market cap; meaningful but not trajectory-altering.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.